Egros Fabrice's Form 4 filing
Syndax Pharmaceuticals Inc (SNDX) · filed Aug 20, 2021
- Accession no.
- 0001562180-21-005491
- Filed
- Aug 20, 2021
- Trade date
- Aug 18, 2021
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 2 non-derivative transactions and 1 derivative transaction. Open-market sales total $246.3K. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Egros FabriceCIK 0001597085 | Director |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Aug 18, 2021 | Common Stock | MOption exerciseAcquired | +15,635 | $7.88 | +$123,203.8 | 31,635 | Direct | |
| Aug 18, 2021 | Common Stock | SSaleDisposed | −15,635 | $15.75F2 | −$246,251.25 | 16,000 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Aug 18, 2021 | Common Stock | MOption exerciseDisposed | 0 | $0.00 | $0 | 0 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F2
The sale prices ranged from $15.58 to $15.94.
Referenced by the price of 1 transaction in Table I.